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Prolactin, a natriuretic hormone, interacting with the renal
dopamine system.
Background. Although prolactin affects sodium and wa-
ter transport across the plasma membrane and interacts with
dopamine in the brain, its role in the kidney is unclear. Here
we examined the effect of prolactin and its possible interaction
with the intrarenal natriuretic hormone dopamine, on proximal
tubular Na+, K+-ATPase activity in vitro and renal function in
anesthetized rats.
Methods. Na+, K+-ATPase activity was measured as ouabain-
sensitive adenosine triphosphate (ATP) hydrolysis in microdis-
sected proximal tubular segments. Renal function was studied
during euvolemic conditions by conventional clearance tech-
niques.
Results. Prolactin induced a dose-dependent inhibition of
proximal tubular Na+, K+-ATPase activity. A maximal in-
hibitory effect of 48% of control was observed at an in vitro
prolactin concentration of 1 lg/mL. This effect was completely
abolished by a dopamine D1 receptor antagonist. In tubules
preincubated with inhibitors of aromatic amino acid decarboxy-
lase (AADC), the rate-limiting enzyme in renal dopamine for-
mation, prolactin had no effect on Na+, K+-ATPase activity. In
rats, prolactin infusion resulted in an increase in urinary sodium,
potassium, and water excretion. These effects were also com-
pletely abolished by the D1 receptor antagonist. Prolactin had
no significant effects on glomerular filtration rate (GFR) or
mean arterial blood pressure.
Conclusion. We conclude that prolactin is a natriuretic hor-
mone which interacts with the renal dopamine system for its
effects. The natriuretic response is associated with inhibition of
proximal tubular Na+, K+-ATPase activity.
Prolactin is a polypeptide involved in various actions
in the body, including lactation, luteotrophic actions, re-
productive and parental behavior, immune response, an-
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giogenesis, and osmoregulation [1]. It has a crucial role in
regulating sodium and water balance in fish which migrate
from salt to fresh water [2]. Several studies have shown
that prolactin regulates ion and fluid transport across the
plasma membrane. An early observation was that pro-
lactin decreased sodium and increased potassium trans-
port across mammary epithelial cells [3, 4]. Prolactin was
also shown to regulate fluid transport across amniotic and
intestinal epithelial cell membranes [5, 6]. Furthermore,
other studies have shown that prolactin regulates urinary
sodium excretion, albeit with conflicting results [7–12].
Prolactin receptors have been found in many different
tissues, including kidneys [13, 14].
It is well known that prolactin interacts with dopamine
in several tissues; lactation is inhibited by dopamine ago-
nists [15], dopamine serves as a prolactin inhibitory fac-
tor in hypothalamus [16], and suppression of endogenous
prolactin with bromocriptin prevents the onset of mater-
nal behavior [17].
Besides its well-known effects in the brain, dopamine
is an intrarenal natriuretic hormone and acts by in-
hibiting the activity of tubular sodium transporters, in-
cluding Na+, K+-ATPase. By its capacity to oppose the
effects of antinatriuretic substances and act permissively
for other natriuretic substances, intrarenal dopamine co-
ordinates the effect of several sodium-regulating factors
[18, 19].
One of the least understood actions of prolactin is reg-
ulation of sodium and water transport. The aim of the
present study was therefore to examine whether pro-
lactin can regulate urinary sodium and water excretion
during euvolemic conditions and, furthermore, to eluci-
date by which mechanism such an effect occurs. Three
topics were studied: the renal localization of prolactin
receptors (PRLR) in the adult rat; the effects of pro-
lactin on renal function, including the effect on proximal
convoluted tubule (PCT) Na+, K+-ATPase activity; and
whether these renal effects were dependent on the renal
dopamine system.
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METHODS
Animals
The in vitro study was performed on male Sprague-
Dawley rats (B & K Universal, Sollentuna, Sweden) aged
40 to 50 days and weighing between 200 and 250 g. The in
vivo study was performed on 19 male Sprague-Dawley
rats (Møllegaard Breeding Center, Copenhagen, Den-
mark) weighing 316 ± 9 g. All animals had free access
to tap water and were fed ad libitum with standard rat
chow containing 0.25% sodium. The experiments were
approved by the local ethics committee for animal ex-
perimentation at Uppsala University and the Karolinska
Institute.
Preparation of PCT segments
Kidney perfusion and tubule microdissection were per-
formed as described [20]. The rats were anesthetized with
an intraperitoneal injection of Mebumal veterinary (5 to
6 mg per 100 g body weight) (Nord Vacc, Stockholm,
Sweden). Following a midline incision, the left kidney
was exposed and perfused with a cold, modified Hank’s
solution containing 0.05% collagenase (Sigma Chemical
Co., St. Louis, MO, USA) and 0.1% bovine serum al-
bumin (BSA) (Behringwerke, Marburg, Germany). The
pH was adjusted to 7.4. The kidney was removed and cut
along its corticopapillary axis into small pyramids that
were incubated for 20 minutes at 35◦C in the perfusion
solution containing 10−3 mol/L butyrate to optimize mi-
tochondrial respiration. The solution was continuously
bubbled with oxygen. After incubation, the tissue was
rinsed with fresh microdissection solution, which had the
same composition as the perfusion solution except that
the CaCl2 concentration was 0.25 mmol/L and collage-
nase and BSA were omitted.
The single PCT segments were manually dissected
(tubular segment length 0.4 to 1.1 mm) from the outer
cortex under a stereomicroscope at 4◦C. The tubule seg-
ments were individually transferred to the concavity of
a bacteriologic slide in a drop of the microdissection so-
lution and photographed for length determination using
an inverted microscope at 100× magnification. Tubules
were stored on ice until dissection was completed, for a
maximum of 30 to 60 minutes.
Preincubation with inhibitors of aromatic amino acid
decarboxylase (AADC)
Renal pyramids were incubated in the microdissection
solution with AADC inhibitors, carbidopa 5×10−4 mol/L
or benserazide 10−5 mol/L, for 30 minutes before and
during the dissection procedure. These drug doses were
selected on the basis of previous studies [21, 22].
Preincubation of tubules with different drugs
Tubule segments were incubated at indicated times at
room temperature, either in 1 lL of microdissection solu-
tion alone (control tubules) or in 1 lL of microdissection
solution containing one or more of the agents mentioned
below (experimental tubules). Prolactin was used in con-
centrations between 1 ng/mL and 1 lg/mL. Prolactin at
these concentrations dose-dependently regulates the ac-
tivity of Na+, K+-2 Cl− cotransporter in epithelial cells
[23]. Tubule segments were preincubated with dopamine
receptor antagonists for 10 minutes before prolactin or
vehicle was added. Doses of dopamine antagonists were
chosen on the basis of previous studies [24, 25].
Determination of Na+, K+-ATPase activity
The preincubation period was stopped by cooling the
tubular segments to 4◦C. The segments were made per-
meable by repeated freezing and thawing. This proce-
dure allows adenosine triphosphate (ATP) and sodium
free access to the interior of the cell. The tubules were
incubated at 37◦C for 15 minutes in a medium containing
(in mmol/L): 70 NaCl, 5 KCl, 10 MgCl2, 1 ethyleneglycol
tetraacetate (EGTA), 100 Tris-HCl, 10 Tris-ATP, and c-
[32P]-ATP (NEN, Boston, MA, USA), 2 to 5 Ci/mmol
in trace amounts (5 nCi/mL). For determination of
ouabain-insensitive ATPase activity, 2 mmol/L ouabain
(USB, Cleveland, OH, USA) was added, NaCl and KCl
were omitted and Tris-HCl was 150 mmol/L. The 32P-
phosphate liberated by hydrolysis of ATP was sepa-
rated by filtration through a Millipore filter (Sartorius
AG, Goettingen, Germany) after absorption of the unhy-
drolyzed nucleotide on activated charcoal, and radioac-
tivity was counted in a liquid scintillation spectrometer.
In each study, total ATPase activity and ouabain-
insensitive ATPase activity were measured on each of five
to eight other tubule segments. Na+, K+-ATPase activity
(pmol of 32Pi hydrolyzed per mm of tubule length per
hour) was calculated as the difference between the mean
value for total ATPase and ouabain-insensitive ATPase
activity, and expressed as an absolute value. Control and
experimental tubules were always run in parallel.
Detection of prolactin receptors in renal tissue
The prolactin receptor (PRLR) was identified by a
commercial available monoclonal mouse antibody, which
recognizes both the long and short isoforms of PRLR,
(Abcam Ltd., Cambridge Science Park, Cambridge, UK).
Briefly, renal cortex or microdissected PCT seg-
ments were homogenized in a buffer containing 65
mmol/L Tris base, 154 mmol/L NaCl, 6 mmol/L sodium
deoxycholate, 1 mmol/L ethylenediamine tetraacetic
acid (EDTA), adjusted to pH 7.4, followed by 10%
NP-40, 1 mmol/L dithiothreitol (DTT), 5 mmol/L
1702 Ibarra et al: Prolactin interacting with dopamine system
phenylmethylsulfonyl fluoride (PMSF), 8 mmol/L
Na2SO4, and complete protease inhibitor (Roche Diag-
nostics Scandinavia AB, Stockholm, Sweden).
A total protein of 10 lg per well was subjected to 8%
sodium dodecyl sulfate-polyacryalmide gel electrophore-
sis (SDS-PAGE). Proteins were transferred to a polyviny-
lidine difluoride (PVDF) transfer membrane, Hybond-P
(Amersham Biosciences, Uppsala, Sweden), and probed
with the primary antibody against PRLR, followed by
horseradish peroxidase (HRP)–conjugated sheep anti-
mouse secondary antibody (Sigma-Aldrich, St Louis,
MO, USA). Immunoreactivity was detected using en-
hanced chemiluminescence (ECL) plus Western blotting
detection system (Amersham Biosciences). Molecular
size determinations were made using Prestained SDS-
PAGE standards (Bio-Rad Laboratories, Sundbyberg,
Sweden).
Renal function
To study the effect of prolactin on renal function
the hormone was administered intravenously into anes-
thetized rats. The animals were anesthetized with an
intraperitoneal injection of Inactin [5-ethyl-5-(1-
methyl-propyl)-2-thio-barbiturate sodium], 120 mg/kg
body weight (Sigma-Aldrich). The rats were then placed
on a servo-controlled heating pad to maintain the rectal
temperature at 37.5◦C. Tracheostomy was performed to
ensure free airways during the experiment. Both jugu-
lar veins were catheterized for infusion and the left
femoral artery for continuous measurements of mean
arterial blood pressure and for blood sampling. Blood
pressure was continuously recorded via a transducer with
a MacLab Instrument (AD Instruments, Hastings, UK)
connected to a Macintosh Power PC 6100 throughout
the experiment. The urinary bladder was catheterized
through a suprapubic incision for urine collection.
The renal function studies were performed during eu-
volemic conditions. After completion of the surgical pro-
cedures, the animals were stabilized for 45 minutes and
during that time given infusions of a Ringer solution
(Fresenius, Kabi, Norway). To determine the glomerular
filtration rate (GFR) a Ringer solution containing [3H]-
methoxy-inulin (4 lCi bolus followed by 2 lCi/hour/100 g
body weight), was given and the total infusion rate in each
animal was 5 mL/hour/kg body weight. Seventy-five mi-
croliters of arterial blood were withdrawn at the midpoint
of each experimental period for estimation of the GFR
and hematocrit.
Three different protocols were used. Group 1, pro-
lactin (N = 7), after two consecutive 20-minute con-
trol sampling periods (C1 and C2), the animals re-
ceived an intravenous bolus injection of 0.3 IU prolactin
(luteotropic hormone, prolactin, from sheep pituitary
glands 32 IU/mg) (Sigma-Aldrich) followed by contin-
uous infusion of 3 IU/hour/kg body weight during four
consecutive 20-minute experimental sampling periods
(E1 to E4). Similar doses of prolactin have been re-
ported to increase urinary sodium excretion in Long-
Evans rats [9]. In group 2, control (N = 6), infusions
and sampling of control rats were identical to that of
prolactin-treated animals except that prolactin was omit-
ted. In group 3, SCH 23390 (D1 receptor antagonist) (N=
6), was used to test the possible interaction of the ef-
fects of prolactin and the dopamine D1 receptor. This
group of rats was subjected to the same prolactin treat-
ment as group 1, but the rats were also treated intra-
venously with the D1-like receptor antagonist SCH23390
(Schering, Kenilworth, NJ, USA). SCH23390 was added
to the infusion solution so that the animals received the
antagonist throughout the experiment, including stabi-
lization and control periods. A bolus injection 30 lg/kg
body weight was given directly after surgery and then
30 lg/hour/kg body weight as a continuous infusion. This
dose has previously been shown to completely inhibit the
effect of dopamine on urinary sodium excretion [26, 27].
Urine analysis
The urine volumes were measured gravimetrically. The
urinary sodium and potassium concentrations were de-
termined by flame photometry (FLM3) (Radiometer,
Copenhagen, Denmark). Urinary osmolality was esti-
mated from the depression of the freezing point. The
amount of [3H]-methoxy-inulin in samples of plasma and
urine was detected using a liquid scintillation counter
(PW 4700; Philips, Amsterdam, The Netherlands). GFR
was estimated from the clearance (Ci) of [3H]-methoxy-
inulin according to the equation:
Ci = (Ui × V)/Pi
where Ui and Pi are the urinary and plasma concentra-
tions of inulin, respectively, and V is the urine flow rate.
Statistical analysis
The results are presented as means ± standard errors of
the mean (SEM). Comparisons within groups have been
performed with Student paired t test and comparisons
between different groups have been performed with Stu-
dent unpaired t test. A P value less than 0.05 was consid-
ered statistically significant.
RESULTS
Several isoforms of prolactin receptors (PRLR) arise
from alternative initiation sites of transcription and gene
splicing. In rodents, one long and three short isoforms
have been described [13, 28]. The antibody used rec-
ognized two bands at ∼70 kD and 40 kD, respectively,
in renal cortex, and microdissected PCTs. The antibody
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Fig. 1. Immunoreactivity of renal localization of prolactin receptors
(PRLR) in renal tissue. A representative blot of PRLR in pituitary gland
(PG), renal cortex (RC), and microdissected renal proximal convoluted
tubular (PTC) segments.
recognized bands of the same size in the positive control,
the pituitary gland (Fig. 1). These bands correspond to the
predicted size of the PRLRs, long and medium short iso-
forms. The medium short isoform was the major isoform
in proximal tubular segments.
To examine the direct effect of prolactin on renal
PCT Na+, K+-ATPase activity, drugs were added to mi-
crodissected tubules at specified times. Prolactin, 1 lg/mL
induced a time-dependent inhibition of PCT Na+,K+-
ATPase activity (Fig. 2), with a maximal inhibitory ef-
fect at 15 minutes’ incubation (Fig. 2A). This time point
was therefore used in further studies. Prolactin decreased
Na+, K+-ATPase activity both when the enzyme was as-
sayed with saturating Na+ concentrations under Vmax
conditions (Na+ 70 mmol/L) (control, 2598 ± 135; pro-
lactin, 1 lg/mL, 1206 ± 95 pmol Pi/mm/hour) (P < 0.05)
and when a lower nonsaturating Na+ concentration of
20 mmol/L was used (control, 1674 ± 116; prolactin,
1 lg/mL, 1421 ± 142 pmol Pi/mm/hour) (P < 0.05). The
inhibitory effect of prolactin during Vmax conditions was
dose-dependent with a maximal effect of 48% of control
at 1 lg prolactin/mL and a threshold effect between 1
and 10 ng/mL (Fig. 2B). The basal plasma concentration
of prolactin in Long-Evans rat has been estimated to be
4.95 ± 1.05 ng/mL [9]. Thus, the concentrations used in
the in vitro experiments are within the physiologic range.
Prolactin had no effect on ouabain insensitive ATPase
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Fig. 2. Effect of prolactin on renal proximal convoluted tubular (PCT)
Na+, K+-ATPase activity. (A) Time dependence. Prolactin was used
in a concentration of 1 lg/mL. Values are mean ± SEM and are
expressed as pmol Pi/mm tubule/hour (N = 3 to 5 per group).∗P < 0.05 vs. control; ∗∗P < 0.05 vs. control and < 0.05 vs. prolactin
15 minutes. Statistical analysis was performed with unpaired Student t
test. (B) Dose dependence. Proximal tubules were incubated with pro-
lactin for 15 minutes. Values are mean ± SEM and are expressed as
pmol Pi/mm tubule/hour (N = 3 to 5 per group). ∗P < 0.05 vs. control.
Statistical analysis was performed with unpaired Student t test. ns is not
significant vs. control.
hydrolysis (control, 1397 ± 173; prolactin, 1 lg/mL, 1530
± 178 pmol Pi/mm/hour).
Prolactin interacts with dopamine in the brain [1,
15, 16]. Here we examined whether prolactin also
interacts with dopamine in the kidney. In tubules
pretreated with an antagonist of the dopamine 2 (D2) re-
ceptor (raclopride, 10−6 mol/L), prolactin still inhibited
Na+, K+-ATPase activity. In contrast, when tubules were
preincubated with a dopamine D1 receptor antagonist
(SCH23390, 10−6 mol/L) the inhibitory effect of prolactin
on Na+, K+-ATPase activity was completely abolished,
suggesting an interaction between prolactin and renal D1
receptors (Fig. 3A).
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Fig. 3. Interaction between prolactin and in-
trarenal dopamine. Proximal tubules were
incubated with prolactin, 1 lg/mL, for 15
minutes. Values are mean ± SEM and are
expressed as pmol Pi/mm tubule/hour. Sta-
tistical analysis was performed with paired
and unpaired Student t test. (A) Dopamine
antagonists. Proximal tubules preincubated
with SCH23390, 10−6 mol/L, or raclopride,
10−6 mol/L (N = 4 to 6 per group). ∗P <
0.05 vs. control. ns is not significant vs. con-
trol. (B) Aromatic amino acid decarboxy-
lase (AADC) inhibitors. Proximal tubules
preincubated with benserazide 10−5 mol/L or
carbidopa 5 × 10−4 mol/L (N = 8 in the
benserazide group and three in the carbidopa
group). ns is not significant vs. benserazide
alone; NS is not significant vs. carbidopa alone.
Neither SCH23390 nor raclopride alone had any effect
on Na+, K+-ATPase activity (data not shown).
To further examine the role of intrarenal dopamine, re-
nal slices were preincubated with two different inhibitors
of AADC, the rate limiting enzyme in renal dopamine
production. As shown in Figure 3B, prolactin did not
decrease Na+, K+-ATPase activity during inhibition of
intrarenal dopamine production.
Next we examined the effect of prolactin on re-
nal function. Rats were treated intravenously with lu-
teotropic hormone isolated from sheep pituitary glands.
The achieved plasma prolactin concentration during the
present experiments can be estimated at 400 ng/mL from
the data of Stier et al [12] where the rats received the
same doses of prolactin and the plasma levels were mea-
sured. This approximates the elevated plasma prolactin
levels found during estrus and lactation [29]. Assuming
that the native hormone, rat prolactin, is as potent as
ovine prolactin, the levels achieved in the current exper-
iments may be consistent with physiologic levels under
such conditions. The same levels of prolactin can also
be seen during antipsychotic treatment. During chlor-
promazine therapy, serum prolactin concentration in-
creases to about 400 ng/mL [30]. These data imply that the
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Fig. 4. Effects of prolactin on renal function. C1 and C2 correspond to
collection periods 1 and 2 before and E1 to E4 correspond to collec-
tion periods 1 to 4 periods after treatment with vehicle, prolactin, and
prolactin and SCH23390 (N = 6 to 7 per group). ∗P < 0.05 vs. control.
Statistical analysis was performed with paired and unpaired Student t
test. (A) Urinary sodium excretion. Values are mean ± SEM and are
expressed as lmol/min/g kidney weight. (B) Urinary flow. Values are
means ± SEM and are expressed as lL/min/g kidney weight. (C) Uri-
nary potassium excretion. Values are mean ± SEM and are expressed
as lmol/min/g kidney weight.
results in the current study may be relevant in physiologic
conditions in females and during antipsychotic treatment
in both men and women.
Prolactin induced an increase in urinary sodium excre-
tion in every rat. The response was variable with a 9.1
± 3.8-fold (E4/C1) increase in urinary sodium excretion.
This effect was associated with an approximate twofold
increase in urinary flow rate and urinary potassium ex-
cretion. All these effects were also abolished by the D1
receptor antagonist (Fig. 4).
Prolactin had no significant effect on urinary osmo-
lality, GFR, mean arterial blood pressure, or hematocrit
(Table 1). The constant hematocrit indicates the presence
of euvolemic conditions throughout the experiment. The
D1 receptor antagonist–treated rats showed a small in-
crease in urine osmolality.
DISCUSSION
Here we present a novel function of prolactin as a po-
tent natriuretic polypeptide, which acts by inhibiting PCT
Na+, K+-ATPase activity. The intrarenal dopamine sys-
tem acts permissively for this effect. The natriuretic po-
tency of prolactin is in the order, or just above that for
atrial natriuretic peptide [31].
Prolactin is a hormone involved in a variety of impor-
tant functions in the body, including stimulation of milk
production, regulation of reproductive functions, protein
synthesis, osmoregulation, as well as the regulation of
ion transport across the plasma membrane [1]. Prolactin
has been shown to regulate fluid transport across cells
in several different tissues such as mammary epithelial
cells, intestinal epithelial cells, and amniotic cells, but rel-
atively little information is available on its effects on
renal ion transport and renal function. Although not
examined in a systematic manner, several studies have
shown that prolactin either induces an antidiuretic and
antinatriuretic response [9–12] or a diuretic and na-
triuretic response [7–9]. These discrepancies can be
explained by contamination with vasopressin in the pi-
tuitary extract, different doses, differences in rat strains,
or differences in the state of hydration prior to in-
jection. Here we studied the renal effects of prolactin
during euvolemic conditions and found a pronounced na-
triuretic and diuretic response which was associated with
a dose-dependent inhibition of proximal tubule Na+, K+-
ATPase activity. Na+, K+-ATPase inhibition did not only
occur during Vmax conditions for Na+, K+-ATPase, but
also when the enzyme was assayed with Na+ 20 mmol/L,
which is the approximate normal intracellular Na+ con-
centration in renal proximal tubular cells. Prolactin treat-
ment had no significant effects on GFR or blood pressure.
There are numerous examples of prolactin interac-
tion with dopamine both in central nervous system and
in peripheral tissues [1]. Dopamine, produced in renal
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Table 1. Renal function
Prolactin Prolactin and SCH23390
Collecting period C1 E4 C1 E4
Glomerular filtration rate mL/min/g kidney weight 1.42 ± 0.17 1.68 ± 0.2 ns 1.58 ± 0.11 1.46 ± 0.18 ns
Mean arterial blood pressure mm Hg 118 ± 3 114 ± 3 ns 116 ± 3 111 ± 3 ns
Urine osmolality mosm/kg/H2O 1915 ± 65 1936 ± 69 ns 1564 ± 120 1930 ± 136 a
Hematocrit% 45 ± 0.6 45 ± 0.7 ns 45 ± 0.5 45 ± 0.6 ns
Values are mean ± SEM. ns, not significant vs. control or vs. prolactin and SCH23390.
aP < 0.05 vs. control.
proximal tubular cells, is a natriuretic hormone and acts
via an inhibition of renal tubular sodium transporters [26,
27, 32, 33]. The renal effects of dopamine are mainly me-
diated via the D1 receptor. Intrarenal dopamine has an
important role in the interactive regulation of salt bal-
ance. Many other natriuretic factors, including atrial na-
triuretic peptide, and nitric oxide exert their effect via
the renal dopamine system [24, 34, 35]. We have shown
that D1 receptor antagonists abolish the renal effects of
atrial natriuretic peptide and isoproterenol and that rats
pretreated with inhibitors of AADC have a blunted re-
sponse to atrial natriuretic peptide [20, 24]. These effects
were explained by the finding that both atrial natriuretic
peptide and isoproterenol regulated the recruitment of
D1 receptors from the interior of the cell to the plasma
membrane where they are physiologically active [20, 24].
Herein we found that the renal effects of prolactin, includ-
ing natriuresis, diuresis, kaliuresis, and Na+, K+-ATPase
inhibition, were abolished by a D1 receptor antagonist.
Furthermore, when tubules were preincubated with dif-
ferent inhibitors of AADC, prolactin no longer inhibited
Na+, K+-ATPase activity.
PRLR have been identified in numerous organs, in-
cluding the central nervous system, pituitary gland, heart,
lung, thymus, spleen, liver, pancreas, adrenal gland,
uterus, skeletal muscle, skin, and kidney [13]. Various
PRLR isoforms have been described in different tissues
and species. We found the long and a medium short iso-
form of PRLR in rat renal cortex and PCT segments.
This localization is in accordance with previous studies
by Mountjoy et al [14], who showed specific binding sites
for prolactin primarily in the proximal tubules.
The PRLR is expressed on proximal tubular cells. Here
prolactin act by inhibiting PCT Na+, K+-ATPase ac-
tivity, the enzyme that mediates active tubular sodium
transport. This effect is rapid and pronounced, and con-
tributes to a natriuretic response. The renal dopamine
system plays a permissive role in the renal effects
of prolactin. During inhibition of intrarenal dopamine
production as well as in the presence of a D1 recep-
tor antagonist the renal response to prolactin is blunted.
Whether prolactin and dopamine interaction involves
an altered production/release of dopamine, a cross-talk
among signaling pathways, heterologous recruitment of
D1 receptors and/or synergism between D1 receptors and
PRLR requires further evaluation.
CONCLUSION
Prolactin is a natriuretic hormone, which interacts with
the renal dopamine system for its full effect. The natri-
uretic response of prolactin involves inhibition of proxi-
mal tubular Na+, K+-ATPase activity.
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